initi coverag market outperform rate price target
initi coverag plx pharma plxp market outperform rate
price target plx drug delivery/formul pre-commerci
compani develop improv formul over-the-counter aspirin asa
provid statist signific superior antiplatelet activ compar enteric-
coat ec asa lower gi ulcer bleed compar immediate-releas
ir asa nineti percent american cardiovascular diseas take
ec asa primarili due common gi ulcer bleed associ ir asa
twenty-f percent patient experi stroke heart attack
take asa believ asa resist clinic data strongli
suggest rate extent asa absorpt ec formul
significantli less ir asa vazalor vazalor provid antiplatelet
activ similar ir asa without gi side effect ec asa solv gi ulcer
bleed issu patient continu experi heart attack
stroke price target base peer index ev/sal ratio
risk-adjust revenu estim discount one year
ninety-two million american live cardiovascular diseas cv mostli
aspirin therapi reduc risk recurr heart attack stroke
approxim patient take ec asa due
high incid gastrointestin gi ulcer bleed ir asa
plx conduct human clinic trial show vazalor provid complet
antiplatelet respons patient compar ec asa
fewer ulcer compar ir asa market opportun meaning
share yield increment annual sale
discount market valu base index peer compani trade
ev/sal multipl
recent market altern asa formul fail good reason neither
product offer improv ec formul cost compar
over-the-counter ec asa expect over-the-counter vazalor
manag care payer refus reimburs exceedingli expens therapi
avail fraction price counter believ
american will pay guard becom one
ec asa patient possibl suffer recurr heart attack stroke
plx alreadi receiv fda clearanc vazalor submit
snda mg dose end plx expect launch
formul plx initi hire sale rep
target acut set larg group practic cardiolog neurolog
endocrinolog second phase launch includ dtc advertis
begin
thomson reuter jmp secur llc
compani report jmp secur llc
report read conjunct import disclosur inform includ attest regul analyst certif
immedi releas ir aspirin asa studi multipl clinic trial decad
clearli document antiplatelet activ reduc incid stroke heart attack
approxim million american take daili low dose aspirin help prevent thromboembol event
includ stroke heart attack earli trial compar immediate-releas asa placebo
show statist signific reduct embol diseas compar placebo immedi releas
asa may also caus peptic ulcer intestin bleed respons gi side effect asa
manufactur develop launch enter coat asa formul releas drug
reach higher ph found small intestin therefor reduc stomach ulcer could
find trial confirm ec asa formul share similar antiplatelet activ immediate-
clinician assum antiplatelet benefit enteric-co asa similar immediate-
releas asa approxim asa market take enteric-co asa eventu
medic commun observ patient take ec asa continu experi stroke
heart attack believ asa resist approxim individu
continu experi platelet-rel diseas spite take daili low-dos ec asa articl start
appear peer-review medic journal show minim antiplatelet activ
patient take enteric-co aspirin aspirin resist studi extens possibl explain
much controversi surround benefit risk assign low-dos asa therapi plx
shed light controversi conduct clinic trial compar ir asa ec asa
vazalor opinion plx conduct trial measur marker antiplatelet therapi includ
time inhibit anti-platelet measur plasma auc acetylsalicyl acid asa
absorpt measur incid gastric ulcer bleed
plx compar immediate-releas ec asa proprietari patent formul vazalor
primari endpoint time achiev thromboxan inhibit time achiev
inhibit ir asa ec asa vazalor hour
respect vazalor achiev statist signific faster onset compar ir asa ec
asa plx also studi pk/pd comparison ir asa ec asa vazalor
show auc three-day trial ng/ml respect compani also
studi gastric ulcer risk compar ir asa show reduct ulcer
studi health volunt seven day show stat sig reduct eros ulcer
vazalor compar ir asa
plx alreadi receiv fda clearanc vazalor expect launch
target million high-risk american compani initi target kol
cardiolog neurolog endocrinolog sell over-the-counter vazalor daili cost patient
opportun meaning market share yield
increment annual sale market valu base index peer compani trade
ev/sal
price target base peer index ev/sal ratio risk-adjust
revenu estim discount one year match peer index ratio
current revenu estim assum probabl approv launch
vazalor alreadi approv formul like receiv fda approv
upon approv version remov probabl discount revenu
estim could increas els equal gross net price/month
market share estim respect
manufactur plx alreadi experienc manufactur delay due inconsist formul
inact ingredi potenti new supplier pass manufactur
regulatori test addit delay occur
regulatori vazalor mg alreadi approv snda mg file soon
expect mg formul approv potenti due clinic manufactur
reason fda may approv mg formul
plx continu incur net loss least product approval/commerci
like earli launch phase compani may rais addit capit would
uncertain dilut impact sharehold valu
competit plx intend enter competit aspirin over-the-counter market multipl larger
plx pharma late-stag pharmaceut compani develop over-the-counter product use proprietari
plxguard deliveri system lead product vazalor formerli known aspertec
over-the-count over-the-counter aspirin design improv efficaci safeti asa
technolog releas duodenum instead stomach reduc stomach irrit improv
efficaci vazalor may overcom aspirin resist increas bioavail compar
ec asa formul repres market plx develop mg
mg version vazalor mg version alreadi approv mg snda expect
end expect product launch
platform focus develop drug releas activ pharmaceut ingredi api
small intestin instead stomach improv safeti efficaci plx technolog use surface-
act lipid includ phospholipid free fatti acid chang releas properti drug
plxguard deliveri system capit differ ph bile acid content
stomach duodenum target releas profil use plxguard technolog unlik current
market aspirin product aspirin enter bloodstream improv bioavail efficaci
addit releas api duodenum instead stomach plx reduc risk bleed
stomach plxguard deliveri system could potenti use creat efficaci
safer nsaid vazalor also first-ev fda-approv liquid-fil aspirin formul
aspirin acetylsalicyl acid asa nsaid commonli use treat pain migrain
fever aspirin also use anti-inflammatori drug aspirin recommend at-risk
popul prevent limit cardiovascular diseas aspirin recommend american heart
associ aha american colleg cardiolog reduc risk heart attack
stroke at-risk patient approxim adult year age use aspirin
prevent cardiovascular diseas american colleg cardiolog recommend aspirin
primari class method secondari prevent cv event aspirin undisputedli consid
gold standard secondari prevent
daili aspirin recommend at-risk patient includ patient histori h/o heart attack
stroke coronari arteri stent h/o coronari bypass surgeri coronari arteri diseas high
risk heart attack diabet one heart diseas risk factor high blood pressur
men year old women aspirin gener recommend individu younger
year age patient heart attack cv event major patient
low-dos mg aspirin
aspirin reduc cv event
aspirin block lipid prostaglandin thromboxan involv pain inflamm
blood clot platelet blood cell fragment help bodi form clot stop bleed
damag blood vessel send signal pick platelet platelet rush site
injuri form plug clot repair damag aspirin irrevers block platelet activ long
asa reach blood stream blood vessel suppli heart muscl brain also
form clot cut blood suppli caus heart attack stroke
clinic studi demonstr aspirin reduc cv event high-risk patient
meta-analysi studi patient baigent et al publish british medic
journal titl collabor meta-analysi randomis trial antiplatelet therapi prevent
death myocardi infarct stroke high-risk patient confirm efficaci antiplatelet
therapi reduc cv event studi defin primari endpoint seriou vascular event
sve includ non-fat myocardi infarct non-fat stroke vascular death meta-analysi
found antiplatelet therapi aspirin reduc combin outcom sve non-fat
myocardi infarct non-fat stroke vascular mortal studi
found absolut reduct sve per patient undergo variou month
treatment studi essenti found high-risk patient took aspirin
one month continu long-term therapi would avoid sve first month
would avoid event next year daili aspirin dose mg found
effect lower dose mg found effect higher daili dose studi
find daili use aspirin lead increas risk upper gi bleed benefit
daili aspirin therapi outweigh gi bleed risk
figur antiplatelet therapi lead fewer cv event
baigent et al collabor meta-analysi randomis trial antiplatelet therapi prevent death
myocardi infarct stroke high-risk patient
baigent et al collabor meta-analysi randomis trial antiplatelet therapi prevent death
myocardi infarct stroke high-risk patient
clinic studi effect aspirin primari prevent cv event
ec aspirin also studi arriv trial determin whether aspirin could use
primari prevent cv event patient moder risk initi cv event arriv trial
conduct europ random patient either mg enter aspirin placebo
arriv trial random patient double-blind placebo-control multi-cent studi
conduct seven countri patient includ men year age women year
age notabl patient high risk gi bleed diabet exclud studi
primari endpoint time first incid cardiovascular death myocardi infarct
unstabl angina stroke transient ischem attack median follow-up time month
patient popul aspirin patient cv event vs placebo patient
gi bleed occur rate aspirin patient vs placebo patient ae rate
similar group arriv trial demonstr ec aspirin play role
primari prevent plx show enteric-co aspirin highli bioavail
complianc daili asa therapi necessari reduc cv event
sundstrm et al conduct larg scale studi sweden danger discontinu low-
dose aspirin impact cv event studi includ patient
patient year age complianc rate three-year follow-up demonstr
patient discontinu aspirin higher rate cv event multivariable-adjust
hazard ratio translat cv event rate patient per year
discontinu aspirin increas risk discontinu aspirin declin time overal
discontinu low-dos aspirin lead increas risk cv event studi found long
patient major surgeri experi bleed prudent continu low-dos
figur patient discontinu aspirin therapi higher rate cv event
sundstrm et al low-dos aspirin discontinu risk cardiovascular event
solut aspirin safeti efficaci issu vazalor plx develop
mg vazalor over-the-counter product vazalor develop use plxguard technolog
design dissolv duodenum instead stomach mg dose vazalor
alreadi approv fda mg approv use clinic data mg
dose approv clinic trial requir mg capsul formul vazalor also
first-ev fda-approv liquid-fil aspirin
plx studi vazalor diabet patient risk cardiovascular event compar studi
measur respons aspirin use immedi releas ir aspirin vazalor
ec aspirin studi random blind triple-crossov patient patient
given either ir aspirin mg vazalor mg ec aspirin mg primari endpoint
antiplatelet activ measur inhibit serum thromboxan gener studi
defin non-respons patient serum level associ thrombot risk
inhibit ng/ml hour daili dose serum thromboxan use
clinic accept biomark antiplatelet activ
vazalor demonstr superior antiplatelet efficaci vs enteric-co aspirin standard care
ir aspirin studi demonstr ec aspirin non-respons rate patient
ir aspirin vazalor patient nonrespons ir
aspirin vazalor compar ec aspirin ir aspirin compar
vazalor high rate unrespons ec aspirin may due lower bioavail
lower inhibit vazalor demonstr medium time inhibit serum
thromboxan hour vs hour ec aspirin vazalor demonstr improv
sig reduct risk acut ulcer vs ir aspirin
figur vazalor bioavail ec ir aspirin
figur patient non-respons aspirin
non-overlap portion non-respons patient
overlap portion patient non-respons two aspirin formul
believ trial clearli demonstr vazalor efficaci safer
current market product studi larg portion ec patient achiev complet
inhibit due low bioavail signific percentag ec aspirin patient show
detect plasma asa level timepoint ir aspirin vazalor show larger
percentag patient asa absorpt inhibit believ low bioavail
primari caus aspirin resist patient instead actual aspirin resist expect
medic commun welcom low-pric superior asa prevent thromboembol
vazalor effect acut gastrointestin eros ulcer compar ir aspirin
studi random single-blind multicent active-control studi patient patient
rang age patient given mg vazalor ir aspirin daili seven
day primari endpoint incid gastrointestin gi eros ulcer eros
ulcer studi demonstr vazalore-tr patient show
lower risk develop multipl eros ulcer vs ir aspirin ir-aspirin patient
develop eros ulcer vs vazalor patient vazalore-tr
patient lower mean number gastric eros vs ir aspirin
vazalor arm also demonstr lower incid gi ulcer vazalore-tr patient
lower rate ulcer vs ir aspirin patient vazalor patient develop ulcer vs
ir-aspirin patient day seven believ studi clearli demonstr
vazalor safer current market ir asa product
vazalor fda approv delay
vazalor mg dose approv fda back over-the-counter product via nda
applic approv base clinic studi mention plx plan submit
snda end approv mg vazalor dose addit clinic trial
requir sinc mg dose alreadi approv fulli expect mg dose approv
vazalor despit approv current market due manufactur delay plx need
altern supplier key vazalor inact ingredi due inconsist plx also
adjust manufactur technolog development scale use clinic trial
commerci scale up plx found new ingredi supplier conduct addit test
formul show preferenti releas small intestin plx type
 meet plan fda discuss issu compani complet
develop scale manufactur batch current gather data type meet
brief packag initi develop manufactur batch submit snda
end mg formul snda file approv expect take month
version approv anticip plx plan launch mg mg
formul
vazalor over-the-counter product plx market use strategi rx product
vazalor target market includ vascular diabet patient total address patient
popul includ patient retail market vascular patient defin
patient atherosclerot cardiovascular diseas ascvd ascvd patient patient prior
event includ heart attack stroke patient also procedur includ cardiac stent
bypass oper carotid oper also includ diabet patient includ patient
diabet without ascvd
price reimburs
vazalor market over-the-counter product promot rx over-the-counter product
vazalor subject reimburs coverag pushback manag care
plx plan price vazalor premium aspirin rx price plx price vazalor
gross-to-net adjust manag care
expect price trade adjust plx provid trade receiv discount pay
pharmaci promot incent get shelf space especi larg retail includ walgreen
notabl amazon mo pt josey expect net
sell price sell concess believ price conserv consid
clear efficaci vs ec aspirin safeti improv compar ir aspirin formul ec asa
cost approxim per day previous mention product highli bioavail
sale forc promot strategi
plx promot vazalor prescription-lik product physician plx target key opinion
leader larg practic acut care set sale rep target market physician
includ cardiologist neurologist endocrinologist endocrinologist top decil
repres physician base physician survey aspirin therapi prescrib
physician state would like prescrib vazalor addit sinc vazalor
over-the-counter product reimburs sale rep restrict plx may
consid dtc campaign soon launch depend sale ramp vazalor expect
vazalor reach market share translat risk-adjust revenu sale
includ probabl approv discount
figur physician highli like prescrib vazalor
vazalor unlik face commerci risk yosprala
yosprala combin rx drug aspirin anti-platelet omeprazol proton pump inhibitor
yosprala sold fix dose either mg aspirin mg omeprazol yosprala
indic secondari prevent cardiovascular event cerebrovascular event patient
risk develop aspirin associ gastric ulcer omeprazol compon releas
immedi reduc gastric acid delayed-releas asa
yosprala develop rx market over-the-counter yosprala struggl commerci due
variou factor despit novel aspirin formul howev believ factor
impact vazalor think investor concern
yosprala clinic trial design show platelet inhibit asa bioavail
manufactur studi safeti primari endpoint primari endpoint yosprala trial
reduct endoscop gastric ulcer six month yosprala compar ec aspirin
demonstr reduct gastric ulcer six month
yosprala also demonstr reduct rate discontinu patient six month
due gi bleed absolut safeti benefit minim ec aspirin patient
develop gastric ulcer six month vs yosprala
yosprala second issu price ec aspirin wide avail over-the-counter compar
yosprala yosprala receiv signific manag care pushback due high cost
requir prior author requir sever pbm approxim prescript
deni manag care vazalor price premium ir asa ec aspirin
offer clear therapeut advantag opinion believ lack proven efficaci high cost
torpedo yosprala launch
figur yosprala monthli sale
plx also develop ibuprofen product use plxguard technolog compani develop
lipid-bas ibuprofen ibuprofen mg over-the-counter product ibuprofen
mg rx market
compani over-the-counter ind file fda demonstr bioequival mg
over-the-counter ibuprofen three dose mg demonstr better gi safeti osteoarthrit
patient equival anti-inflammatori analges effect vs rx ibuprofen six-week
endoscopi trial plx may file nda
plx pharma licens agreement board regent univers texa
portfolio patent amend compris famili patent includ
composit matter method manufactur method treatment patent cover
aspirin vazalor ibuprofen nsaid plx pharma five patent
cover method use composit matter lecithin oil nsaid latest
expir march
import intellectu properti ip releas patent cover vazalor
mg compani also famili patent expir cover ph depend carrier
target releas drug along gi tract key patent platform reli api
releas beyond stomach
natasha giordano presid ceo ms giordano appoint presid chief execut
offic director effect januari previous ms giordano serv interim chief
execut offic clearpoint learn inc posit held may novemb
also serv clearpoint board director decemb novemb
previous ms giordano serv chief execut offic healthcar corpor
america januari august june august ms giordano
serv chief oper offic chief execut offic presid member
board director xanodyn pharmaceut inc brand specialti pharmaceut compani
develop commerci capabl focus pain manag prior serv
presid america cegedim dendrit formerli dendrit intern inc
senior vice presid global custom busi cegedim dendrit
cegedim dendrit sinc serv group presid global
busi major custom vice presid global sale earlier career
work nine year parke-davi own warner lambert sever sale market
posit includ strateg allianc manag sale integr ms giordano hold
bachelor scienc degre nurs wagner colleg
rita oconnor chief offic ms oconnor join plx pharma chief
offic effect juli previous serv chief offic kent place school
all-girl colleg preparatori school sinc juli previous chief offic
chief inform offic xanodyn pharmaceut inc integr specialti pharmaceut
compani focus women health pain manag prior chief
offic treasur adam respiratori therapeut specialti pharmaceut compani focus
over-the-counter prescript product treatment respiratori disord earlier career
held posit increas respons seven-year tenur schering-plough corpor
began career deloitt touch ms oconnor licens certifi public account
earn bachelor scienc account rutger univers
efthymio deliargyri md chief medic offic dr efthymio maki deliargyri appoint
chief medic offic august dr deliargyri tripl board-certifi physician intern
medicin cardiolog intervent cardiolog career clinic medicin academia
signific biotech experi global leadership role recent dr deliargyri founder
manag director scienc strategi consult group provid expert advic
solut scientif regulatori strateg commerci challeng compani engag
cardiovascular arena previous dr deliargyri serv global medic
lead cardiovascular franchis medicin compani led global medic strategi
global medic affair late-stag activ success fda ema present
lead approv cangrelor europ origin join compani
vice presid european medic director base munich germani
prior join medicin compani dr deliargyri serv chief cardiolog intervent
cardiolog athen medic center athen greec assist
professor cardiolog director intravascular laboratori ivu wake forest univers
winston-salem nc dr deliargyri intern recogn origin
research cardiovascular diseas thrombosi author public top
journal includ new england journal medicin journal american colleg
cardiolog circul origin research recogn multipl award includ
prestigi societi cardiac angiographi intervent scai fellowship award
best origin research intervent cardiolog unit state dr deliargyri receiv
doctor medicin degre kapodistrian univers athen school medicin
complet resid train intern medicin tuft univers school medicin
fellowship cardiolog intervent cardiolog univers north carolina chapel hill
figur calendar event
plx pharmadateeventregulatoryfinancingspatentstri resultsclin trial mm recent complet million convert prefer stock convert prefer new supplier key manufactur delay aspertec due inconsist key inact pharma hire commerci execut prepar futur launch plx pharma retain dr efthymio deliargyri chief medic pharma inc announc close regist direct nci grant research novel aspirin formul prevent colorect oconnor appoint chief offic plx pharma dipexium announc merger aspirin-induc ulcer attenu aspirin-phosphatidylcholin random clinic trial comparison ibuprofen-phosphatidylcholin ibuprofen gastrointestin safeti analges efficaci osteoarthrit plx pharma inc plxp
consolid incom statement plxp thousand except per share good sold- gross oper expens research gener total oper oper non-oper incom interest interest tax tax incom ep non-gaap fulli taxednmnmnmnmnmnmnmnmnmnmnmnmnmnmfd share margin expens analysisgross margin net net revenu research year growthnet incom non-gaap fulli taxednmnmnmnmnmnmnmnmnmnmnmnmnmnmfd share plx pharma inc plxp
plx pharma late-stag pharmaceut compani develop over-the-counter product use proprietari plxguard deliveri system lead
product vazalor formerli known aspertec over-the-count over-the-counter aspirin design improv efficaci
safeti asa technolog releas duodenum instead stomach reduc stomach irrit improv efficaci
vazalor may overcom aspirin resist increas bioavail compar ec asa formul repres
market plx develop mg mg version vazalor mg version alreadi approv mg snda
expect end expect product launch
manufactur plx alreadi experienc manufactur delay due inconsist formul inact ingredi
potenti new supplier pass manufactur regulatori test addit delay occur
regulatori vazalor mg alreadi approv snda mg file soon expect mg formul
approv potenti due clinic manufactur reason fda may approv mg formul
plx continu incur net loss least product approval/commerci like earli launch phase
compani may rais addit capit would uncertain dilut impact sharehold valu
competit plx intend enter competit aspirin over-the-counter market multipl larger competitor
